Teva And Celltrion Gain Arthritis Advantage On Rituximab
Truxima Biosimilar Now Available In Rheumatoid Arthritis Indication In US
Teva and Celltrion’s Truxima rituximab biosimilar is now available with a rheumatoid arthritis indication in the US, the firms have revealed, giving it a potential advantage over Pfizer’s Ruxience version.
You may also be interested in...
Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.
Henlius says it can now pursue a “differentiated strategy” for its HLX01 rituximab biosimilar in China, after winning approval for a key rheumatoid arthritis indication from the NMPA.
Teva is “uniquely qualified” to succeed with biosimilars thanks to the dual branded and generic mindsets that it can bring to the table, Christine Baeder, senior vice president and chief operating officer of Teva’s US generics division, tells Generics Bulletin in the second part of an exclusive interview.